Abstract
Osteoprotegerin (OPG), a soluble tumor necrosis factor receptor family molecule, protects endothelial cells from apoptosis in vitro and promotes neovascularization in vivo. Angiogenesis may be crucial for the course and outcome of sarcoidosis. In this study, we evaluated the clinical usefulness of OPG and its ligand, a soluble receptor activator of nuclear factor-kappaB (sRANKL), in bronchoalveolar lavage fluid (BALF) in patients with sarcoidosis (BBS, Besniera-Boeck-Schaumann disease). We studied 22 BBS patients and 15 healthy volunteers as a control group. The levels of OPG, sRANKL, and interleukin-18 (IL-18) were measured by the Elisa method. The BALF levels of sRANKL and IL-18 were higher in the BBS patients compared with controls [sRANKL: 2.12 (0.82–10.23) vs. 1.12 (0.79–4.39) pmol/l, p = 0.03; IL-18: 34.29 (12.50–133.70) vs. 13.05 (12.43–25.88) pg/ml, p = 0.001]. There were no significant differences between the concentration of OPG in the BBS patients and healthy controls [0.22 (0.14–0.81) vs. 0.23 (0.14–0.75) pmol/l]. In the BBS patients we found correlations between sRANKL and IL-18 in BALF (r = 0.742, p = 0.0001) and between OPG and lung diffusing capacity for carbon monoxide (DLCO) (r = −0.528, p = 0.029). Receiver-operating characteristic (ROC) curve was applied to find the cut-off for the BALF level of sRANKL (BBS vs. healthy: 1.32 pmol/l). We conclude that OPG and sRANKL may have usefulness in clinical evaluation of BBS patients.
The original version of this chapter has been revised. An erratum to this chapter can be found at DOI 10.1007/978-3-319-44488-8_11
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Thoracic Society (1995) Standardization of spirometry 1994 update. Am J Respir Crit Care Med 152:1107–1136
Amin MA, Rabquer BJ, Mansfield PJ, Ruth JH, Marotte H, Haas CS, Reamer EN, Koch AE (2010) Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis 69:2204–2212
Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139–146
Chen ES, Moller DR (2008) Etiology of sarcoidosis. Clin Chest Med 29:365–377
Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95:1046–1057
Costabel U, Hunninghake GW (1999) ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 14:735–737
Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I (2006) Osteoprotegerin (OPG) -a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118:1901–1908
Crowley LE, Herbert R, Moline JM, Wallenstein S, Shukla G, Schechter C, Skloot GS, Udasin I, Luft BJ, Harrison D, Shapiro M, Wong K, Sacks HS, Landrigan PJ, Teirstein AS (2011) ‘Sarcoid like’ granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med 54:175–184
Goswami S, Sharma-Walia N (2015) Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer 15:935
Kieszko R, Krawczyk P, Jankowska O, Chocholska S, Król A, Milanowski J (2007) The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respir Med 101:722–728
Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O’Donnell CJ, Kathiresan S (2010) Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 30:1849–1854
Liu DH, Yao YT, Cui W, Chen K (2010) The association between interleukin-18 and pulmonary sarcoidosis: a meta-analysis. Scand J Clin Lab Invest 70:428–432
Müller-Quernheim J (1998) Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 12:716–738
Piotrowski WJ, Kiszałkiewicz J, Górski P, Antczak A, Górski W, Pastuszak-Lewandoska D, Migdalska-Sęk M, Domańska-Senderowska D, Nawrot E, Czarnecka KH, Kurmanowska Z, Brzeziańska-Lasota E (2015) Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients. BMC Immunol 16:58
Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P (2010) Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 33:2561–2566
Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B, Aukrust P (2006) Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26:857–863
Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol 29:975–980
Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, Kurimoto M, Hiraga Y, Tatsuno T, Abe S, Sato N (2001) IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 166:642–649
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J (2014) Sarcoidosis. Lancet 9923:1155–1167
Zielonka TM, Demkow U, Białas B, Filewska M, Zycinska K, Radzikowska E, Szopiński J, Skopińska-Rózewska E (2007) Modulatory effect of sera from sarcoidosis patients on mononuclear cell-induced angiogenesis. J Physiol Pharmacol 58:753–766
Conflicts of Interest
The authors had no conflicts of interest to declare in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Naumnik, W., Naumnik, B., Niklińska, W., Ossolińska, M., Chyczewska, E. (2016). Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study. In: Pokorski, M. (eds) Respiratory Treatment and Prevention. Advances in Experimental Medicine and Biology(), vol 944. Springer, Cham. https://doi.org/10.1007/5584_2016_44
Download citation
DOI: https://doi.org/10.1007/5584_2016_44
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44487-1
Online ISBN: 978-3-319-44488-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)